The objectives of this study are to review the safety and efficacy of Actilyse Vial (hereafter referred to as "Actilyse") in post-marketing use for treatment of acute ischemic stroke, through investigating followings; 1. Unknown adverse events (especially serious adverse events) 2. Frequency (Incidence) and trend of adverse events under the actual practice 3. Factors on the safety profile of Actilyse 4. Factors on the efficacy profile of Actilyse
Study Type
OBSERVATIONAL
Enrollment
265
Clinical effectiveness assessed by 30 days-mortality
Time frame: 30 days
Number of patients with adverse events
Time frame: up to 30 days
Number of patients with clinically significant abnormal findings in physical examination
Time frame: up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.